Pazopanib+Sorafenib — Competitive Intelligence Brief

Pazopanib+Sorafenib (Pazopanib+Sorafenib) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor combination VEGFR, PDGFR, RAF kinase Oncology Small molecule

Target snapshot

Pazopanib+Sorafenib (Pazopanib+Sorafenib) — Technical University of Munich. This combination of two tyrosine kinase inhibitors blocks multiple receptor pathways (VEGFR, PDGFR, RAF kinase) to inhibit tumor angiogenesis and cell proliferation.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pazopanib+Sorafenib TARGET	Pazopanib+Sorafenib	Technical University of Munich	phase 3	Multi-targeted tyrosine kinase inhibitor combination	VEGFR, PDGFR, RAF kinase
TACE plus sorafenib	TACE plus sorafenib	Guangxi Medical University	phase 3	Combination therapy (locoregional procedure + multi-kinase inhibitor)	VEGFR, PDGFR, RAF kinases (sorafenib component)
Adjuvant tislelizumab plus lenvatinib	Adjuvant tislelizumab plus lenvatinib	Guangxi Medical University	phase 3	PD-1 inhibitor + multi-targeted tyrosine kinase inhibitor combination	PD-1 (tislelizumab); FGFR, VEGFR, RET, KIT (lenvatinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor combination class)

1. Technical University of Munich · 1 drug in this class